Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report

Takahashi, Shota; Sato, Yuki; Sato, Yoshiharu; Sato, Yoshiharu; Sato, Yoshiharu; Hirabayashi, Ryosuke; Hara, Shigeo; Takahashi, Yutaka; Tomii, Keisuke

doi:10.1016/j.jtocrr.2024.100639

Public

Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report

Published in JTO Clinical and Research Reports • Jan 19, 2024

Authors:

Shota Takahashi

Yuki Sato

Yoshiharu Sato

Abstract

Histologic transformation is one of the mechanisms of resistance to EGFR tyrosine kinase inhibitor in patients with NSCLC with EGFR mutation. The transformation from adenocarcinoma to squamous cell carcinoma (SCC) has been recently recognized as a mechanism of resistance to osimertinib. The prognosi...

Subject

Osimertinib

Medicine

Adenocarcinoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!